ABSTRACT
1. The concentrations of interleukin 1 (IL-1) and interleukin 2 (IL-2) produced in the supernatants of peripheral blood mononuclear cell cultures from patients with advanced cancer were measured to identify some of the causes of the immunological impairment characteristic of malignant disease. 2. Mononuclear cells obtained from 19 cancer patients were stimulated to produce IL-1 and IL-2 and compared with those of healthy controls. A severe reduction of both IL-1 and IL-2 activity was observed. 3. There was no correlation between the lower number of OKT4+ cells observed in these patients and the levels of IL-2 production. The removal of monocytes did not bring IL-2 levels to normal. Impaired IL-2 production could not be restored to normal by addition of IL-1. 5. These results suggest that exogenous IL-1 and IL-2 may be useful in cancer immunotherapy.
Subject(s)
Interleukin-1/biosynthesis , Interleukin-2/biosynthesis , Leukocytes, Mononuclear/metabolism , Neoplasms/blood , Adult , Female , Humans , Immune Tolerance , Leukocytes, Mononuclear/analysis , Lymphocyte Activation , Male , Middle Aged , Neoplasms/immunology , Neoplasms/pathology , Phytohemagglutinins/pharmacology , Tetradecanoylphorbol Acetate/pharmacologyABSTRACT
The concentrations of interleukin 1 (IL-1) and interleukin 2 (IL-2) produced in the supernatants of peripheral blood mononuclear cell cultures from patients with advanced cancer were measured to identify some of the causes of the immunological impairment characteristic of malignant disease. Mononuclear cells obtained from 19 cancer patients were stimulated to produce IL-1 and IL-2 and compared with those of healthy controls. A severe reduction of both IL-1 and IL-2 activity was observed. There was no correlation between the lower number of OKT4+ cells observed in these patients and the levels of IL-2 production. The removal of monocytes did not bring IL-2 levels to normal. Impaired IL-2 production could not be restored to normal by addition of IL-1. These results suggest that exogenous IL-01 and IL-2 may be useful in cancer immunotherapy
Subject(s)
Adult , Middle Aged , Humans , Male , Female , Interleukin-1/biosynthesis , Interleukin-2/biosynthesis , Leukocytes, Mononuclear/metabolism , Neoplasms/immunology , Kidney Neoplasms/immunology , Leukocytes, Mononuclear/analysis , Lung Neoplasms/immunology , Colonic Neoplasms/immunology , Neoplasms/pathology , Phytohemagglutinins/pharmacology , Tetradecanoylphorbol Acetate/pharmacology , Lymphocyte Activation , Urinary Bladder Neoplasms/immunology , Uterine Cervical Neoplasms/immunologyABSTRACT
The effect of Escherichia coli enterotoxin STa on the primary and secondary immune response in F1 (CBA x C57 B1/10) mice immunized against sheep red blood cells (SRBC) was investigated. Modulating action on the IgM and IgG response was found to be dependent on the dose-time administration of the toxin. Immunosuppression of the primary response on the 4th day after immunization was observed when the toxin was injected 15 min before the SRBC, followed by immunostimulation on the 6th day after antigen (Ag) injection. Moreover, toxin administration 48 h before SRBC caused immunosuppression of the primary immune response on the 4th and 6th days. On the other hand, the IgM and IgG secondary immune response, determined 6 days after boosting, was greatly enhanced by toxin administration 15 min before priming (day 0) or boosting (day 26) and 48 h before priming. The same response was suppressed by toxin administration 48 h before booster antigen injection.
